SUTRO BIOPHARMA INC.

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 May 2024 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

30 Apr 2024 05:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

02 Apr 2024 03:18:56 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

25 Mar 2024 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

06 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

04 Jan 2024 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

14 Dec 2023 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

11 Dec 2023 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

04 Dec 2023 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

21 Nov 2023 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

13 Nov 2023 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

22 Oct 2023 01:25:00 By Nasdaq GlobeNewswire

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

16 Oct 2023 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

19 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

30 Aug 2023 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

10 Aug 2023 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

26 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

03 Jun 2023 13:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

31 May 2023 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

15 May 2023 05:00:01 By Nasdaq GlobeNewswire